ABSK021 Food Effect Study in Healthy Subjects
This is a randomized, open-label, two-sequence, two-cycle, cross-over study to evaluate the relative bioavailability of ABSK021 after single-dose fasting and high-fat postprandial administration in healthy subjects
Neoplasms
DRUG: ABSK021 with fed state|DRUG: ABSK021 with fasted state
Cmax, Pharmacokinetics parameters in fasting state and fed state, 4 weeks|AUC0-âˆž, Pharmacokinetics parameters in fasting state and fed state, 4 weeks|AUC0-t, Pharmacokinetics parameters in fasting state and fed state, 4 weeks|Tmax, Pharmacokinetics parameters in fasting state and fed state, 4 weeks
Adverse Events, Safety and tolerability measure by number of subjects who experience adverse events, Through study completion, an average of 4 weeks
This is a single-center, arandomized, open label, two-sequence, two-cycle, cross-over study. Up to 16 healthy subjects will be enrolled in this study. Subjects will be randomized into sequence A or sequence B (8 subjects in each study sequence), and receive single oral doses of ABSK021 on 2 occasions separated by a washout period of at least 14 days (7 half-life of ABSK021 in human). Screening will occur up to 28 days prior to the first dose. And the end of treatment visit will occur 14 days after the last dose of ABSK021.